Amalgamated Bank Acquires 2,435 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Amalgamated Bank raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 1.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 142,147 shares of the biotechnology company’s stock after purchasing an additional 2,435 shares during the period. Amalgamated Bank’s holdings in Exelixis were worth $4,733,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Principal Securities Inc. raised its position in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares in the last quarter. USA Financial Formulas bought a new position in Exelixis during the 4th quarter worth $32,000. Kestra Investment Management LLC acquired a new position in Exelixis in the 4th quarter valued at $39,000. UMB Bank n.a. lifted its position in shares of Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 553 shares during the period. Finally, V Square Quantitative Management LLC grew its holdings in shares of Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 425 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Price Performance

EXEL opened at $37.65 on Friday. The company’s 50 day moving average price is $34.42 and its two-hundred day moving average price is $31.54. The firm has a market capitalization of $10.54 billion, a price-to-earnings ratio of 21.27, a PEG ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $38.43.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, equities research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Activity

In other news, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total transaction of $694,600.75. Following the transaction, the director now directly owns 33,514 shares of the company’s stock, valued at $1,248,396.50. This represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 112,807 shares of company stock valued at $4,126,373. Company insiders own 2.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EXEL. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research note on Thursday, February 13th. Citigroup boosted their target price on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Morgan Stanley upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $30.00 to $40.00 in a research report on Monday, January 27th. JMP Securities restated a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research report on Thursday, January 23rd. Finally, Truist Financial raised their target price on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.